Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 33 Breast Neoplasms 26 Triple Negative Breast Neoplasms 17 Prostatic Neoplasms 16 Fallopian Tube Neoplasms 11 Neoplasms 9 Fanconi Anemia, Complementation Group D1 7 Endometrial Neoplasms 7 Pancreatic Neoplasms 6 Glioma 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Neoplasm Metastasis 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Carcinosarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2

Interventions

Cisplatin 51 Gemcitabine 26 toripalimab 20 Radiotherapy, Intensity-Modulated 19 Fluorouracil 16 Capecitabine 16 camrelizumab 15 Docetaxel 14 nimotuzumab 12 Radiotherapy 10 Drug Therapy 10 apatinib 9 Nivolumab 9 sintilimab 8 endostar protein 7 Specimen Handling 7 Magnetic Resonance Spectroscopy 7 Immune Checkpoint Inhibitors 7 tislelizumab 6 spartalizumab 6 Chemoradiotherapy 6 Cetuximab 6 Bevacizumab 6 pembrolizumab 5 nedaplatin 5 S 1 (combination) 5 Radiation 5 Paclitaxel 5 Endostatins 5 anlotinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Nasopharyngeal Carcinoma × olaparib × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡